Teva Just Hit Investment Grade. That Does Not Mean the Stock Is.

On September 4, S&P upgraded Teva from BB+ to BBB-. Three weeks earlier, Moody's made the same move.Fitch did it in May. For the first time since the 2017 bankruptcy, Teva holds investment-grade credit ratings from all three major agencies.

The stock has responded accordingly. Since hitting a 52-week low of $18.21, Teva has more than doubled, trading around $36 and up 92% over the rolling year. A market cap of $42 billion now sits behind a company that was worth less than $20 billion just months ago.

The credit upgrade is real and earned. The question is whether the stock has priced in the good news, the operating risks, and the valuation that comes with investment-grade status.

The debt story is the easy part. Teva's net debt stands at $12.9 billion, down sharply from the peak levels that carried it into Chapter 11. The net debt-to-EBITDA ratio is 2.8 times right now, with S&P projecting it will fall below 3.0x by 2027 and reach a target range of 2.5x to 3.0x by 2028. Free cash flow over the trailing twelve months hit $1.35 billion, up 51% year over year. Gross margins have expanded 80 basis points to 55.4%. These are exactly the metrics credit raters watch, and they are moving in the right direction.

Teva's "Pivot to Growth" strategy — launched in 2023 and now in what CEO Richard Francis calls the "acceleration phase" — is what drove the deleveraging. The company is reshaping from a legacy generics business into a biopharma company anchored by three branded growth engines: AUSTEDO for tardive dyskinesia, AJOVY for migraine prevention, and UZEDY for seizures. Together, the innovative portfolio reached a 2026 revenue midpoint of $3.7 billion, up from roughly $3.3 billion a year ago. In the second quarter, AUSTEDO grew 33%, AJOVY surged 56%, and UZEDY rose 43%. Teva raised its full-year 2026 revenue guidance by $75 million, and each of the three brands got a guidance bump.

The branded story is the reason the credit story works. Higher-margin specialty revenue pulls up EBITDA, which pulls down leverage, which pulls down borrowing costs, which improves cash flow. It is a mechanical flywheel, and right now it is spinning.

Here is where the stock story diverges from the credit story.

Investment grade matters to bondholders. It matters less — and sometimes the wrong way — to equity investors.

When a company crosses into investment grade, it becomes eligible for funds that are restricted to investment-grade holdings. That can push up bond prices and lower borrowing costs. It can also attract equity capital from mandates that exclude speculative-grade names. But that inflow is about access, not quality. It does not change the fact that Teva, at its current valuation, asks the equity buyer to fund the next phase of growth at a premium price.

Teva trades at 21 times trailing EV/EBITDA. Forward P/E is roughly 43. For comparison, Viatris — a similarly structured generics-and-specialty company — trades at a fraction of that multiple. The generic pharmaceutical business is structurally competitive: prices erode, patents expire, and the next entrant always charges less. Teva's own generics segment fell 15% in the second quarter, largely from the fading contribution of generic Revlimid. Management expects an even softer generics year ahead in 2026.

This creates the central tension. Teva's branded drugs are growing fast, but they represent only about half of total revenue. The other half — generics — is a declining business. AUSTEDO, the largest branded drug, is expected to generate roughly $2.5 billion in 2026 revenue. That is impressive for a single product, but it is also a drug in a niche neurological indication with a defined patient pool. Growth of 33% sounds excellent until you ask what 33% on a $2.5 billion base requires and whether the market is large enough to sustain it.

There is also the acquisition bill to factor in. In the second quarter, Teva reported a non-GAAP EPS of just $0.02, well below the $0.08 analysts expected — and a GAAP net loss of $576 million. The miss was almost entirely due to a $724 million charge for the Emalex Biosciences acquisition, which Teva treated as an asset purchase and expensed as in-process R&D. Emalex brings a single promising asset: ecopipam, a first-in-class treatment for pediatric Tourette syndrome that is NDA-ready. A $724 million write-off for one asset is a statement of intent, not proof of return. The net debt-to-EBITDA ratio was 2.8x including the charge and 2.3x excluding it — a gap that shows how much the acquisition masked the underlying leverage improvement.

Teva's pipeline tells a longer-term story. Beyond ecopipam, there is olanzapine LAI launching in the fourth quarter of 2026, a biosimilars platform with 15 products already on the market and 14 in the pipeline, and early-stage programs in immunology and celiac disease. The biosimilars segment is a particular wildcard: Teva expects to exceed its $800 million revenue target by 2027, but biosimilars carry their own pricing pressure, and the market is increasingly crowded.

What happens next to the stock depends on three things. First: can the branded portfolio keep growing at the rates that justify the multiple? AUSTEDO and AJOVY have been strong, but they are building on a relatively small base, and the next few quarters will show whether that growth is durable or front-loaded. Second: can generics stop declining, or at least stabilize? Teva expects a softer generics year in 2026, which means the branded half of the business has to carry the entire revenue conversation. Third: does deleveraging continue on schedule? S&P projects leverage below 3.0x by 2027 and cash conversion at 80% of earnings. If that holds, the credit story stays intact. If it stalls, the investment-grade status — newly won and newly fragile — can reverse.

The stock's 92% run over the past year has been remarkable. But the question for someone looking at Teva today is not whether the credit upgrade is deserved. It is whether the equity valuation, which has already priced in the turnaround, the branded growth, the pipeline, and the investment-grade reclassification, leaves room for the execution risk that remains.

Teva is no longer a distressed name. It is a growth-at-a-price name, with a declining generics backbone and a branded future that still needs to prove it can sustain the multiple. The credit raters have done their job. The equity investor's job is harder: deciding whether the next phase of growth is already bought at the current price.